Search Results
Your search for ,ASh matches 1521 pages
Showing 1 - 50The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma
The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
ASH Announces 2025 Hematologists to Be Honored With Top Awards and Distinguished Lectures
The American Society of Hematology (ASH) will recognize 11 hematologists who have made significant contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, on December 6–9. Rainer Storb, MD, of Fred...
Updates in Systemic Light-Chain Amyloidosis
Systemic amyloid light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chains, produced by clonal CD38-positive plasma cells, as insoluble amyloid fibrils in vital organs. It is a disease that can progress rapidly and is fatal without treatment. The past decade...
ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions
The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.” —Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Benefit Suggested for Early Treatment of Advanced-Stage, Very Low–Tumor Burden Follicular Lymphoma
In the phase III JCOG1411/FLORA trial of patients with untreated advanced-stage, very low–tumor burden follicular lymphoma, rituximab induction delayed disease progression to high–tumor burden follicular lymphoma and delayed the initiation of cytotoxic chemotherapy, according to Japanese...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Former UNMC Cancer Center Director, Kenneth H. Cowan, MD, PhD, Dies at 77
Kenneth H. Cowan, MD, PhD, served for 24 years as Director of the National Cancer Institute (NCI)-designated cancer center at the University of Nebraska Medical Center (UNMC), now called the Nebraska Medicine Fred & Pamela Buffett Cancer Center in Omaha. Dr. Cowan died on December 15, 2024, at ...
Primary Analysis of ZUMA-2: Bruton Tyrosine Kinase Inhibitor–Naive Relapsed or Refractory Mantle Cell Lymphoma
ZUMA-2 is a single-arm, multicenter, open-label phase II study that investigated leukapheresed adults with mantle cell lymphoma whose disease was refractory to or had relapsed after up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy; anti-CD20...
In Case You Missed It: Additional Studies of Interest From ASH 2024
A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...
Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...
Is Clonal Cytopenia of Undetermined Significance Distinct From Lower-Risk Myelodysplastic Syndrome?
High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informative with regard to prognosis, management, and clinical trial eligibility, said Zhuoer (Zoey) Xie, MD, ...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
Early-Stage Classic Hodgkin Lymphoma
“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.” —Muhammad Ali Long-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Belinda Avalos, MD, Begins Term as 2025 ASH President
Belinda Avalos, MD, Professor of Medicine and a senior advisor to the President of Atrium Health Levine Cancer, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2025. Overview Dr. Avalos is a physician-scientist with a special clinical...
Studies Point to the Role of Diet in Hematologic Malignancies
According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The speakers said their studies may ultimately lead to dietary interventions that could alter the course of ...
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (BTK) inhibitor–naive mantle cell lymphoma. The findings from cohort 3 of...
Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an increased risk of leukemia compared with other first responders or members of the public who were not...
Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL
At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 883), Alexey Danilov, MD, PhD, of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center, Duarte, California, reported that single-agent epcoritamab led...
CAR T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma: ZUMA-2
Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 showed that 39% of patients with relapsed/refractory mantle cell lymphoma were alive after 5 years; patients in these cohorts received brexucabtagene autoleucel, the only chimeric antigen receptor (CAR) T-cell therapy to have 5-year...
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Bruton’s tyrosine kinase (BTK) inhibitor–naive mantle cell lymphoma. The findings from cohort 3 of...
Autologous Stem Cell Transplantation May Not Improve Survival in Patients With MCL and Undetectable Minimal Residual Disease
Researchers have revealed that high-dose chemotherapy followed by autologous stem cell transplantation may not benefit patients with mantle cell lymphoma (MCL) who are in remission following initial treatment, according to new findings presented by Fenske et al at the 2024 American Society of...
Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL
The addition of blinatumomab to chemotherapy may improve disease-free survival in pediatric patients newly diagnosed with National Cancer Institute (NCI) standard-risk B-cell acute lymphoblastic leukemia (ALL) at average or high risk of relapse, according to new findings presented by Rau et al at...
Bicistronic CAR T-Cell Therapy Achieved Durable Remissions in Children With Relapsed/Refractory B-Cell ALL
A follow-up study investigating the coadministration of CD19- and CD22-targeted chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) found the therapy is safe and effective and achieved durable remissions in these patients, ...
Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant
Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease (GVHD) by cultivating a healthy gut microbiome, according to research presented by Paredes et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...
Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL
Researchers have found that the noncovalent Bruton's tyrosine kinase inhibitor (BTK) pirtobrutinib may offer superior progression-free survival in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to recent findings presented by Sharman et al at the 2024...
Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL
A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens,...
High-Fiber Diet May Slow Disease Progression to Multiple Myeloma
Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week controlled diet with additional health coaching for 20 patients as well as experiments in mice, is ...
Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes
Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He discusses how these findings could have significant implications for future microbiome-modulating...
Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study
Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, an anti-colony stimulating factor 1 receptor monoclonal antibody, in the setting of chronic...
Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, on the Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: A Multi-Center Observational Study
Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, of Fred Hutch Cancer Center and the University of Washington School of Medicine, presented results of a prospective, multicenter observational study across 13 predominantly academic centers enrolling adult patients with acute myeloid leukemia. The...
Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models
Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). The researchers evaluated a preclinical mouse model of GVHD with...
Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in a population of patients with TP53-aberrrant chronic lymphocytic leukemia (CLL). The triplet...
John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib
John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combination of imetelstat and ruxolitinib in patients with intermediate- or high-risk myelofibrosis...
John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment
John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses the results of the phase III BOREAS study evaluating the efficacy and safety of single-agent navtemadlin vs best available therapy in patients with relapsed/refractory myelofibrosis who had previously received JAK...
Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease
Timothy S. Fenske, MD, of the Medical College of Wisconsin presented an initial report from the ECOG-ACRIN EA4151 phase III randomized trial exploring outcomes of autologous hematopoietic cell transplantation (ASCT) in mantle cell lymphoma. The researchers randomized patients in first complete...
Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease
Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed the addition of blinatumomab to chemotherapy in newly diagnosed childhood standard-risk B-cell...
Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, discusses the results of a recent trial (Abstract 1011) evaluating the time-limited, combination therapy of the noncovalent Bruton’s tyrosine kinase inhibitor pirtobrutinib with the BCL2 inhibitor venetoclax and the CD20 ...
